A comparative analysis of biosimilar vs originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma; a propensity ‐score weighted multicenter approach
Source: American Journal of Hematology - Category: Hematology Authors: F Lanza, F Saraceni, A Pezzi, M Martino, A Bosi, N Cascavilla, P Musto, E Zuffa, M Tani, C Cellini, D Laszlo, F Bonifazi, Tags: Correspondence Source Type: research
More News: Filgrastim | Hematology | Lymphoma | Myeloma | Neulasta | Neupogen | Stem Cell Therapy | Stem Cells